Latest Advancements in Biotherapeutics

References

1. Venter J.C. Adams M.D. Myers E.W. Li P.W. Mural R.J. Sutton G.G. Smith H.O. Yandell M. Evans C.A. Holt R.A. Gocayne J.D. Amanatides P. Ballew R.M. Huson D.H. Wortman J.R. Zhang Q. Kodira C.D. Zheng X.H. Chen L. Skupski M. Subramanian G. Thomas P.D. Zhang J. Gabor Miklos G.L. Nelson C. Broder S. Clark A.G. Nadeau J. McKusick V.A. Zinder N. Levine A.J. Roberts R.J. Simon M. Slayman C. Hunkapiller M. Bolanos R. Delcher A. Dew I. Fasulo D. Flanigan M. Florea L. Halpern A. Hannenhalli S. Kravitz S. Levy S. Mobarry C. Reinert K. Remington K. Abu-Threideh J. Beasley E. Biddick K. Bonazzi V. Brandon R. Cargill M. Chandramouliswaran I. Charlab R. Chaturvedi K. Deng Z. Francesco V.D. Dunn P. Eilbeck K. Evangelista C. Gabrielian A.E. Gan W. Ge W. Gong F. Gu Z. Guan P. Heiman T.J. Higgins M.E. Ji R.R. Ke Z. Ketchum K.A. Lai Z. Lei Y. Li Z. Li J. Liang Y. Lin X. Lu F. Merkulov G.V. Milshina N. Moore H.M. Naik A.K. Narayan V.A. Neelam B. Nusskern D. Rusch D.B. Salzberg S. Shao W. Shue B. Sun J. Wang Z.Y. Wang A. Wang X. Wang J. Wei M.H. Wides R. Xiao C. Yan C. Yao A. Ye J. Zhan M. Zhang W. Zhang H. Zhao Q. Zheng L. Zhong F. Zhong W. Zhu S.C. Zhao S. Gilbert D. Baumhueter S. Spier G. Carter C. Cravchik A. Woodage T. Ali F. An H. Awe A. Baldwin D. Baden H. Barnstead M. Barrow I. Beeson K. Busam D. Carver A. Center A. Cheng M.L. Curry L. Danaher S. Davenport L. Desilets R. Dietz S. Dodson K. Doup L. Ferriera S. Garg N. Gluecksmann A. Hart B. Haynes J. Haynes C. Heiner C. Hladun S. Hostin D. Houck J. Howland T. Ibegwam C. Johnson J. Kalush F. Kline L. Koduru S. Love A. Mann F. May D. McCawley S. McIntosh T. McMullen I. Moy M. Moy L. Murphy B. Nelson K. Pfannkoch C. Pratts E. Puri V. Qureshi H. Reardon M. Rodriguez R. Rogers Y.H. Romblad D. Ruhfel B. Scott R. Sitter C. Smallwood M. Stewart E. Strong R. Suh E. Thomas R. Tint N.N. Tse S. Vech C. Wang G. Wetter J. Williams S. Williams M. Windsor S. Winn-Deen E. Wolfe K. Zaveri J. Zaveri K. Abril J.F. Guigó R. Campbell M.J. Sjolander K.V. Karlak B. Kejariwal A. Mi H. Lazareva B. Hatton T. Narechania A. Diemer K. Muruganujan A. Guo N. Sato S. Bafna V. Istrail S. Lippert R. Schwartz R. Walenz B. Yooseph S. Allen D. Basu A. Baxendale J. Blick L. Caminha M. Carnes-Stine J. Caulk P. Chiang Y.H. Coyne M. Dahlke C. Mays A.D. Dombroski M. Donnelly M. Ely D. Esparham S. Fosler C. Gire H. Glanowski S. Glasser K. Glodek A. Gorokhov M. Graham K. Gropman B. Harris M. Heil J. Henderson S. Hoover J. Jennings D. Jordan C. Jordan J. Kasha J. Kagan L. Kraft C. Levitsky A. Lewis M. Liu X. Lopez J. Ma D. Majoros W. McDaniel J. Murphy S. Newman M. Nguyen T. Nguyen N. Nodell M. Pan S. Peck J. Peterson M. Rowe W. Sanders R. Scott J. Simpson M. Smith T. Sprague A. Stockwell T. Turner R. Venter E. Wang M. Wen M. Wu D. Wu M. Xia A. Zandieh A. Zhu X. The sequence of the human genome. Science 2001 291 5507 1304 1351 10.1126/science.1058040 11181995
   [Google Scholar]
2. Farokhzad O.C. Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009 3 1 16 20 10.1021/nn900002m 19206243
   [Google Scholar]
3. June C.H. O’Connor R.S. Kawalekar O.U. Ghassemi S. Milone M.C. CAR T cell immunotherapy for human cancer. Science 2018 359 6382 1361 1365 10.1126/science.aar6711 29567707
   [Google Scholar]
4. High K.A. Roncarolo M.G. Gene therapy. N. Engl. J. Med. 2019 381 5 455 464 10.1056/NEJMra1706910 31365802
   [Google Scholar]
5. Tibbitt M.W. Dahlman J.E. Langer R. Emerging frontiers in drug delivery. J. Am. Chem. Soc. 2016 138 3 704 717 10.1021/jacs.5b09974 26741786
   [Google Scholar]
6. Weiner L.M. Surana R. Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010 10 5 317 327 10.1038/nri2744 20414205
   [Google Scholar]
7. Jadhav K. Abhang A. Kole E.B. Gadade D. Dusane A. Iyer A. Sharma A. Rout S.K. Gholap A.D. Naik J. Verma R.K. Rojekar S. Peptide–drug conjugates as next-generation therapeutics: Exploring the potential and clinical progress. Bioengineering 2025 12 5 481 10.3390/bioengineering12050481 40428099
   [Google Scholar]
8. Pallapati A.R. Korkmaz F. Rojekar S. Sims S. Misra A. Gimenez-Roig J. Gangadhar A. Laurencin V. Gumerova A. Cheliadinova U. Sultana F. Vasilyeva D. Cullen L. Schuermann J. Munitz J. Kannangara H. Parte S. Pevnev G. Burganova G. Tumoglu Z. Witztum R. Wizman S. Kramskiy N. Igel L. Sen F. Ranzenigo A. Macdonald A. Hutchison S. Teunissen A.J.P. Burkart H. Saxena M. Ginsburg Y. Goosens K. Zhou W. Ryu V. Moldavski O. Barak O. Pazianas M. Caminis J. Bhasin S. Fitzgerald R. Kim S.M. Quinn M. Haider S. Appt S. Frolinger T. Rosen C.J. Lizneva D. Gupta Y.K. Yuen T. Zaidi M. Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer’s disease models. J. Clin. Invest. 2025 135 17 182702 10.1172/JCI182702 40663423
   [Google Scholar]
9. Parit S. Manchare A. Gholap A.D. Mundhe P. Hatvate N. Rojekar S. Patravale V. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy. Int. J. Pharm. 2024 659 124211 10.1016/j.ijpharm.2024.124211 38750981
   [Google Scholar]
10. Rojekar S. Gholap A.D. Jadhav K. Shevalkar G. Sugandhi V.V. Pai R. Parikh K. Prajapati M.K. Desai N. Vora L.K. Ingle R.G. Paudel K.R. Exploring protein aggregation in biological products: From mechanistic understanding to practical solutions. AAPS PharmSciTech 2025 26 6 189 10.1208/s12249‑025‑03189‑2 40629131
    [Google Scholar]
11. Rojekar S. Pallapati A.R. Gimenez-Roig J. Korkmaz F. Sultana F. Sant D. Haeck C.M. Macdonald A. Kim S.M. Rosen C.J. Barak O. Meseck M. Caminis J. Lizneva D. Yuen T. Zaidi M. Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration. eLife 2023 12 88898 10.7554/eLife.88898 37334968
    [Google Scholar]
12. Sant D. Rojekar S. Gera S. Pallapati A.R. Gimenez-Roig J. Kuo T.C. Padilla A. Korkmaz F. Cullen L. Chatterjee J. Shelly E. Meseck M. Miyashita S. Macdonald A. Sultana F. Barak O. Ryu V. Kim S.M. Robinson C. Rosen C.J. Caminis J. Lizneva D. Haider S. Yuen T. Zaidi M. Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay. Ann. N. Y. Acad. Sci. 2023 1521 1 67 78 10.1111/nyas.14952 36628526
    [Google Scholar]
13. FDA Roundup January 16 2024 2024 Available from: https://www.fda.gov/news-events/press-announcements/fda-roundup-january-16-2024
14. Frangoul H. Ho T.W. Corbacioglu S. CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia. Reply. N. Engl. J. Med. 2021 384 23 91 10.1056/NEJMc2103481 34107197
    [Google Scholar]
15. Global biotherapeutics market size & industry report [2035]. 2025 Available from: https://www.rootsanalysis.com/reports/biotherapeutics-market.html
16. CAR-T cell therapy market research 2024-2025: Size, forecasts, trials, and trends - Approved CAR-T therapies and late-stage clinical trials that could reach commercialization soon - ResearchAndMarkets.com. 2025 Available from: https://www.businesswire.com/news/home/20250106985719/en/CAR-T-Cell-Therapy-Market-Research-2024-2025-Size-Forecasts-Trials-and-Trends---Approved-CAR-T-Therapies-and-Late-stage-Clinical-Trialsthat-Could-Reach-Commercialization-Soon---ResearchAndMarkets.com.
17. AI’s potential to accelerate drug discovery needs a reality check. Nature 2023 622 7982 217 217 10.1038/d41586‑023‑03172‑6 37817040
    [Google Scholar]
18. Czaplewski L. Bax R. Clokie M. Dawson M. Fairhead H. Fischetti V.A. Foster S. Gilmore B.F. Hancock R.E.W. Harper D. Henderson I.R. Hilpert K. Jones B.V. Kadioglu A. Knowles D. Ólafsdóttir S. Payne D. Projan S. Shaunak S. Silverman J. Thomas C.M. Trust T.J. Warn P. Rex J.H. Alternatives to antibiotics—A pipeline portfolio review. Lancet Infect. Dis. 2016 16 2 239 251 10.1016/S1473‑3099(15)00466‑1 26795692
    [Google Scholar]
19. Batool S. Shahid I. Iftikhar M. Haider B. Deeba F. Saleem R.S.Z. Pisum sativum L. peel extract based biogenic silver nanoparticles as antibiotic adjuvants to reverse multidrug resistance in bacteria. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
20. Maru S. Borah D. Hojaisa S. Sarma I. Mavi A.K. Singh T. Gulati A. Goswami R.K. CAR-T cell therapy: Pioneering immunotherapy paradigms in cancer treatment. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
21. Munshi N.C. Anderson L.D. Shah N. Madduri D. Berdeja J. Lonial S. Raje N. Lin Y. Siegel D. Oriol A. Moreau P. Yakoub-Agha I. Delforge M. Cavo M. Einsele H. Goldschmidt H. Weisel K. Rambaldi A. Reece D. Petrocca F. Massaro M. Connarn J.N. Kaiser S. Patel P. Huang L. Campbell T.B. Hege K. San-Miguel J. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 2021 384 8 705 716 10.1056/NEJMoa2024850 33626253
    [Google Scholar]
22. Neelapu S.S. Tummala S. Kebriaei P. Wierda W. Gutierrez C. Locke F.L. Komanduri K.V. Lin Y. Jain N. Daver N. Westin J. Gulbis A.M. Loghin M.E. de Groot J.F. Adkins S. Davis S.E. Rezvani K. Hwu P. Shpall E.J. Chimeric antigen receptor T-cell therapy — Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018 15 1 47 62 10.1038/nrclinonc.2017.148 28925994
    [Google Scholar]
23. Li S. Chen L. Fu Y. Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. J. Nanobiotechnology 2023 21 1 232 10.1186/s12951‑023‑01992‑2 37480102
    [Google Scholar]
24. Yang C. Yang J. Lu A. Gong J. Yang Y. Lin X. Li M. Xu H. Nanoparticles in ocular applications and their potential toxicity. Front. Mol. Biosci. 2022 9 931759 10.3389/fmolb.2022.931759 35911959
    [Google Scholar]
25. Desai H. Shah P. Sawant V. Singh R. Design and preliminary in vitro investigation on Core–Shell nanoparticles laden in situ gel for corneal neovascularization. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
26. Tang Z. Fan X. Chen Y. Gu P. Ocular nanomedicine. Adv. Sci. 2022 9 15 2003699 10.1002/advs.202003699 35150092
    [Google Scholar]
27. Gao S. Lin H. Zhang H. Yao H. Chen Y. Shi J. Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme‐catalyzed cascade reaction. Adv. Sci. 2019 6 3 1801733 10.1002/advs.201801733 31168441
    [Google Scholar]
28. Zhan Z. Zeng W. Liu J. Zhang L. Cao Y. Li P. Ran H. Wang Z. Engineered biomimetic copper sulfide nanozyme mediates “don’t eat me” signaling for photothermal and chemodynamic precision therapies of Breast cancer. ACS Appl. Mater. Interfaces 2023 15 20 24071 24083 10.1021/acsami.3c01047 37159843
    [Google Scholar]
29. Mundekkad D. Cho W.C.S. Biomimetic Fe3O4 nanozymes promote apoptosis in breast cancer cell lines via free radical scavenging and inhibition of RelA/p65. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
30. Mansur A.A.P. Mansur H.S. Nanozyme-based cancer nanotheranostics: Emerging applications and challenges in brain cancer therapeutics. J. Nanotheranostics 2025 6 1 4 10.3390/jnt6010004
    [Google Scholar]
31. Zhou X. Feng S. Xu Q. Li Y. Lan J. Wang Z. Ding Y. Wang S. Zhao Q. Current advances in nanozyme-based nanodynamic therapies for cancer. Acta Biomater. 2025 191 1 28 10.1016/j.actbio.2024.11.023 39571955
    [Google Scholar]
32. Wang J. Li B. Qiu L. Qiao X. Yang H. Dendrimer-based drug delivery systems: History, challenges, and latest developments. J. Biol. Eng. 2022 16 1 18 10.1186/s13036‑022‑00298‑5 35879774
    [Google Scholar]
33. Rojekar S. Bhowmik D.D. Gupta J.S. Kamandar P.A. Gholap A.D. Hatvate N.T. Dendrimers-based hydrogels and nanogels for drug delivery. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
34. Chauhan A.S. Dendrimers for drug delivery. Molecules 2018 23 4 938 10.3390/molecules23040938 29670005
    [Google Scholar]
35. Kaurav M. Ruhi S. Al-Goshae H.A. Jeppu A.K. Ramachandran D. Sahu R.K. Sarkar A.K. Khan J. Ashif Ikbal A.M. Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment. Front. Pharmacol. 2023 14 1159131 10.3389/fphar.2023.1159131 37006997
    [Google Scholar]
36. Negahdari B. Jalalvand M. Esmaeili F. Falahzadeh K. Mazloumi M. Shahsavari G. Bayat E. Zandsalimi F. Talebkhan Y. Nematollahi L. Cetuximab scFv-modified 5-FU loaded chitosan nanoparticles: “A novel therapeutic platform.”. Curr. Pharm. Biotechnol. 2026 27 5
    [Google Scholar]
37. Marques A.C. Antibody-Functionalized Nanoparticles for Targeted Drug Delivery in Cancer Therapy. Cancer Personalized Treatment: Nanomedicine, Combined Therapy, and Artificial Intelligence in Treatment of Tumors. Rezaei N. Cham Springer Nature Switzerland 2025 349 390 10.1007/978‑3‑032‑00773‑5_297
    [Google Scholar]
38. Liu Y.T. Zhang L.L. Jiang Z.Y. Tian X.S. Li P.L. Wu P.H. Du W.T. Yuan B.Y. Xie C. Bu G.L. Zhong L.Y. Yang Y.L. Li T. Zeng M.S. Sun C. Applications of Artificial Intelligence in biotech drug discovery and product development. MedComm 2025 6 8 70317 10.1002/mco2.70317 40740484
    [Google Scholar]
39. Sui C. Wu H. Li X. Wang Y. Wei J. Yu J. Wu X. Cancer immunotherapy and its facilitation by nanomedicine. Biomark. Res. 2024 12 1 77 10.1186/s40364‑024‑00625‑6 39097732
    [Google Scholar]
40. Regulatory Science to 2025: Strategic reflection on collaborative frameworks. 2024 Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf